These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 33336070)

  • 21. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
    García-Teijido P; Cabal ML; Fernández IP; Pérez YF
    Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
    Cyprian FS; Akhtar S; Gatalica Z; Vranic S
    Bosn J Basic Med Sci; 2019 Aug; 19(3):227-233. PubMed ID: 30915922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
    Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
    J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges.
    de Melo Gagliato D; Buzaid AC; Perez-Garcia J; Cortes J
    BioDrugs; 2020 Oct; 34(5):611-623. PubMed ID: 32870473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
    Brasó-Maristany F; Sansó M; Chic N; Martínez D; González-Farré B; Sanfeliu E; Ghiglione L; Carcelero E; Garcia-Corbacho J; Sánchez M; Soy D; Jares P; Peg V; Saura C; Muñoz M; Prat A; Vivancos A
    Front Oncol; 2021; 11():710596. PubMed ID: 34616675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.
    De Santis P; Perrone M; Guarini C; Santoro AN; Laface C; Carrozzo D; Oliva GR; Fedele P
    Explor Target Antitumor Ther; 2024; 5(1):232-250. PubMed ID: 38464390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    Landry I; Sumbly V; Vest M
    Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How I treat metastatic triple-negative breast cancer.
    Caparica R; Lambertini M; de Azambuja E
    ESMO Open; 2019; 4(Suppl 2):e000504. PubMed ID: 31231572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
    Cipriano É; Mesquita A
    Breast Cancer (Auckl); 2021; 15():11782234211002491. PubMed ID: 33814914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic triple-negative breast cancer: Established and emerging treatments.
    Puri A; Reddy TP; Patel TA; Chang JC
    Breast J; 2020 Sep; 26(9):1793-1796. PubMed ID: 32578306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC.
    Vetrei C; Passariello M; Froechlich G; Rapuano Lembo R; Sasso E; Zambrano N; De Lorenzo C
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
    Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
    Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atezolizumab for the treatment of breast cancer.
    Reddy SM; Carroll E; Nanda R
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
    [No Abstract]   [Full Text] [Related]  

  • 39. Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer.
    Hao X; Gao X; Yin S; Jiang Z
    Transl Breast Cancer Res; 2023; 4():6. PubMed ID: 38751481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the Management of Early-Stage Triple-Negative Breast Cancer.
    Bhardwaj PV; Wang Y; Brunk E; Spanheimer PM; Abdou YG
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.